Proposal for new calcineurin inhibitor listings on the Pharmaceutical Schedule

11 August 2020 - As part of PHARMAC’s Annual Tender process, PHARMAC is proposing to list two new medicines on ...

Read more →

Proposal to fund an additional brand of budesonide with eformoterol

30 July 2020 - PHARMAC is seeking feedback on a proposal to fund an additional brand (DuoResp Spiromax) of two ...

Read more →

Modifying funded access to mifepristone and misoprostol

2 July 2020 - PHARMAC is pleased to announce a decision to: ...

Read more →

Proposal to award sole supply of infliximab in DHB hospitals

21 May 2020 - PHARMAC is proposing to award sole supply of infliximab, a biologic medicine used to treat a ...

Read more →

Proposal to fund modified release pancreatic enzyme granules (Creon Micro)

2 April 2020 - PHARMAC is seeking feedback on a proposal to fund a new modified-release granule formulation of pancreatic ...

Read more →

PHARMAC seeking views on new cystic fibrosis medicine

24 January 2020 - PHARMAC has reached a provisional agreement with medicine supplier Vertex to fund ivacaftor (marketed as Kalydeco) ...

Read more →

Fees and charges proposal 2020-21

20 January 2020 - The TGA is undertaking a consultation through its website to seek stakeholder's views on TGA’s proposed fees ...

Read more →

Proposal to fund betamethasone dipropionate with calcipotriol (Enstilar) foam spray for psoriasis

15 January 2020 - PHARMAC is seeking feedback on a proposal to fund a new topical psoriasis medicine, betamethasone dipropionate ...

Read more →

It's given me so much hope': PHARMAC announces breast cancer drug deal

15 January 2020 - Wiki Mulholland has watched friends die around her since her terminal breast cancer diagnosis 18 months ...

Read more →

PHARMAC seeking views on new breast cancer medicine

15 January 2020 - PHARMAC has reached a provisional agreement with medicine supplier Pfizer to fund palbociclib (marketed as Ibrance) ...

Read more →

Funding of vitamin A oral liquid

18 December 2019 - PHARMAC is pleased to announce that PHARMAC has approved the use of the Exceptional Circumstances framework ...

Read more →

Proposal to fund mepolizumab for the treatment of severe refractory eosinophilic asthma

18 December 2019 - PHARMAC is seeking feedback on a proposal to fund mepolizumab (Nucala), a new treatment for severe ...

Read more →

Proposal to widen funded access to lenalidomide for multiple myeloma

16 December 2019 - PHARMAC is seeking feedback on a proposal to widened funded access to lenalidomide (Revlimid) to include ...

Read more →

Proposals for funding in the blood, alimentary and immunosuppressant therapy areas

9 December 2019 - PHARMAC is seeking feedback on proposals to widen funded access to medicines in the blood, alimentary ...

Read more →

Proposal to widen access to rituximab and change the funded brand for all funded indications excluding rheumatoid arthritis

31 October 2019 - PHARMAC is seeking feedback on a proposal to make changes to the funded brand of rituximab, ...

Read more →